Kinetic Concepts wins FDA clearance for tissue repair product

The product utilizes the company’s proprietary Strattice technology, which is a sterile reconstructive tissue matrix that supports tissue regeneration. The Strattice technology is a porcine-based, acellular dermal matrix that acts as a scaffold that is revascularized and repopulated with cells by the host, ultimately converting it into functional, living tissue.

According to the company, the new product provides an environment that supports wound healing and can be used in the management of a wide range of wound types, including pressure ulcers, diabetic ulcers, venous ulcers, chronic vascular ulcers, surgical wounds, trauma wounds and other acute wounds.

Catherine Burzik, president and CEO of Kinetic Concepts, said: “The use of the LifeCell tissue matrix in wound management is further evidence of our commitment to our strategy of utilizing the Strattice technology to further expand our advanced wound care business along the spectrum of care with a product that will promote wound healing and closure in conjunction with the vacuum assisted closure therapy.”